Novel antibacterial macrolides: Synthesis of 15-membered diolides

Journal of Organic Chemistry

Volumn 67, Issue 26, 2002, Pages 9146-9152

  Ohara, Takafumi ^a   Kume, Masaharu ^a   Narukawa, Yukitoshi ^a   Motokawa, Kiyoshi ^a   Uotani, Kouichi ^a   Nakai, Hiroshi ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBACTERIAL MACROLIDES;

MACROMOLECULES; SYNTHESIS (CHEMICAL); X RAY ANALYSIS;

BACTERIOLOGY;

8A OXA 8A HOMOERYTHROMYCIN A CYCLIC 11,12 CARBONATE; ANTIINFECTIVE AGENT; ERYTHROMYCIN; LACTAM DERIVATIVE; LACTONE DERIVATIVE; MACROLIDE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONFORMATION; DRUG ACTIVITY; DRUG SYNTHESIS; LITERATURE; MOLECULAR MECHANICS; STEREOCHEMISTRY; STRUCTURE ANALYSIS; X RAY ANALYSIS;

ANTI-BACTERIAL AGENTS; BACTERIA; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; ERYTHROMYCIN; MICROBIAL SENSITIVITY TESTS; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037184830     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo020458e     Document Type: Article

References (28)

1. Kurath, P.; Jones, P. H.; Egan, R. S.; Perun, T. J. Experientia 1971, 27, 362.
2. For recent reviews, see: (a) Chu, D. T. W. Med. Res. Rev. 1999, 19, 497-520.
3. (b) Bryskier, A. Expert Opin. Invest. Drugs 1999, 8, 1171-1194.
4. (c) Bryskier, A. Expert Opin. Invest. Drugs 1997, 6, 1697-1709.
5. (d) Chu, D. T. W. Expert Opin. Invest. Drugs 1995, 4, 65-94.
6. (e) Wu, Y. J. Curr. Pharm. Design. 2000, 6, 181-223.
7. (f) Wu, Y. J.; Su, W. G. Curr. Med. Chem. 2001, 8, 1727-1758.
8. Morimoto, S.; Takahashi, Y.; Adachi, T.; Nagate, T.; Watanabe, Y.; Omura, S. J. Antibiot. 1990, 43, 286.
9. For example, see: (a) 11-membered analogues: Kirst, H. A.; Wind, J. A.; Paschal, J. W. J. Org. Chem. 1987, 52, 4359.
10. (b) 12-Membered analogues: Kibwage, I. O.; Busson, R.; Janssen, G.; Hoogmartens, J.; Vanderhaeghe H.; Brache J. J. Org. Chem. 1987, 52, 990.
11. (c) 13-Membered analogues: Burnell-Curty, C.; Faghih, R.; Pagano, T.; Henry, R. F.; Lartey, P. A. J. Org. Chem. 1996, 61, 5153.
12. (d) 14-Membered azalide: Jones, A. B. J. Org. Chem. 1992, 57, 4361.
13. Bright, G. M.; Nagel, A. A.; Bordner, J.; Desai, K. A.; Dibrino, J. N.; Nowakowska, J.; Vincent, L.; Watrous, R. W.; Sciavolino, F. C.; English, A. R.; Retsema, J. A.; Anderson, M. R.; Brennan, L. A.; Borovoy, R. J.; Cimochowaski, C. R.; Faiella, J. A.; Girard, D.; Herbert, C.; Manousos, M.; Mason, R. J. Antibiot. 1988, 41, 1029.
14. Murphy, H. W.; Stephens, V. C.; Conine, J. W. USA Patent 3417077 (1968).
15. (b) Slawinski, W.; Bojarska-Dahlig, H.; Glabski, T.; Dziegielewska, I.; Biedrzycki, M.; Naperty, S.; Rec, J. R. Nether. Chem. Soc. 1975, 94, 236.
16. (c) Hauske, J. R.; Kostek, G. J. Org. Chem. 1982, 47, 1595.
17. Flynn, E. H.; Murphy, H. W.; McMahon, R. E. J. Am. Chem. Soc. 1955, 77, 3104-3105.
18. Yasukata, T.; Narukawa, Y. Unpublished results from these laboratories. This method for Cbz-protection of the cladinosyl moiety of erythromycin derivatives was originally invented.
19. Baskaran, S.; Islam, I.; Raghavan, S.; Chandrasekaran, S. Chem. Lett. 1987, 1175.
20. (b) Kraft, P.; Tochtermann, W. Liebigs Ann. Chem. 1995, 8, 1409.
21. Wilkening, R. R.; Ratcliffe, R. W.; Doss, G. A.; Bartizal, K. F.; Graham, A. C.; Herbert, C. M. Bioorg. Med. Chem. Lett. 1993, 3, 1287.
22. (b) Wilkening, R. R.; Ratcliffe, R. W.; Doss, G. A.; Mosley, R. T.; Ball, R. G. Tetrahedron, 1997, 53, 16923.
23. X-ray crystal structures and crystal data for 13a and 13b are reported in the Supporting Information.
24. For basic hydrolysis of 11,12-cyclic carbonate of erythromycin analogues, see: (a) Faghih, R.; Burnell-Curty, C.; Lartey, P. A.; Peterson, A.; Klein, L. L.; Bennani, Y. L.; Nellans, H. N. Eur. J. Med. Chem. 1999, 34 (3), 261.
25. (b) Hunt, E.; Tyler, J. W. J. Chem. Soc., Perkin. Trans. 2, 1990, 2157.
26. Cahiez, G.; Alexakis, A.; Normant, J. F. Tetrahedron Lett. 1978, 3013.
27. Cannon, K. C.; Know, G. R. In Handbook of Grignard Reagents; Silverman, G. S.; Rakita, P. E., Ed.; Marcel Dekker: New York, 1996; pp 497-526.
28. MICs (minimum inhibitory concentrations) were determined by NCCLS (National Committee for Clinical Laboratory Standards) recommended microbroth dilution methods using cation-adjusted Mueller Hinton broth (Difco Laboratories, Detroit, MI).